Real-time continuous glucose monitoring in randomized control trials.
Several recent randomized controlled trials offer firm evidence supporting the efficacy and safety of real-time continuous glucose monitoring (RT-CGM) in type 1 diabetes mellitus (T1DM). Improved metabolic control with significant lowering of glycated hemoglobin (A1C) along with other parameters of glycemia, and without a concomitant increase in hypoglycemia, has been demonstrated. However, poor compliance in adolescents has been a limiting factor in that age group. The potential of RT-CGM of reducing hypoglycemia in well-controlled individuals with T1DM is anticipated but remains to be confirmed. The current high cost of this technology may limit clinical experience in routine clinical settings.
Battelino
Tadej
T
UMC-University Children' Hospital, Medical Faculty, University of Ljubljana, Slovenia. tadej.battelino@mf.uni-lj.si
Phillip
Moshe
M
D000293:Adolescent; D000328:Adult; D001786:Blood Glucose / Q000032:analysis*; D002648:Child; D003922:Diabetes Mellitus, Type 1 / Q000097:blood* / Q000188:drug therapy*; D006442:Glycated Hemoglobin / Q000032:analysis*; D006801:Humans; D007328:Insulin / Q000008:administration & dosage*; D007332:Insulin Infusion Systems; D018670:Monitoring, Ambulatory / Q000379:methods; D016032:Randomized Controlled Trials as Topic / Q000379:methods*; D055815:Young Adult
D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007328:Insulin